There are multiple testing modalities[1]. We have examined them decades ago[2]. Various other markers have been proposed[3]. Ase the UK has just announced[4]:
The UK National Screening Committee (UK NSC) has recommended that all UK nations implement targeted prostate cancer screening for men aged 45 to 61 who have both a BRCA2 gene change that increases cancer risk and a family history of breast, ovarian, pancreatic or prostate cancer. As part of this approach, eligible men would be offered a prostate specific antigen (PSA) test every two years. This final recommendation modifies a draft recommendation the UK NSC made in November 2025, which also included men with BRCA1 gene changes. Since then, the committee has been consulting with organisations, experts and the public, and considering the latest evidence on the risks and benefits of screening these groups, among others. “Today’s announcement will be disappointing for many people, but the PSA test currently used to help detect prostate cancer isn’t effective enough to support wider screening, as shown in multiple large-scale trials,” explains Dr Ian Walker, Cancer Research UK’s Executive Director of Policy. “Screening should only be introduced when the benefits outweigh the harms, including unnecessary and invasive overtreatment, and right now, the evidence is only strong enough to screen men aged 45 to 61 with BRCA2 gene changes and a relevant family history.” We now urge governments across the UK to accept the UK NSC’s recommendation and begin to implement targeted screening. At the same time, they should continue to invest in research that brings us closer to effective screening for more men. We also aim to be part of that work. Over the past three years, Cancer Research UK has invested £28m to find new and better ways to prevent, detect and treat cancer, and we will continue to help more men affected by prostate cancer live longer, better lives.
MedCityNews notes[5]:
On Wednesday, 60 organizations representing providers and patients with cancer submitted a letter to Robert F. Kennedy Jr., secretary of Health and Human Services, urging him to protect the U.S. Preventive Services Task Force (USPSTF). USPSTF is an independent panel of experts in disease prevention. It provides recommendations for clinical preventive services like screenings, counseling services and medications. However, the task force hasn’t convened in over a year. And last week, Kennedy fired the vice chairs of USPSTF: John Wong, a professor of medicine at Tufts University, and Esa Davis, professor of medicine at the University of Maryland.
Ironically the USPSTF had taken a stand comparable to the UK, Namely, limit PSA testing. Just to put things in perspective, PSA and %Free tests cost about $50. Here in the US one can get them at Quest and other Labs without a doctors order. If one were to be tested ever six months, and the results examined over time, then any significant change would present as a warning.
We have shown decades ago that PSA was useful, but only if examined in an ongoing temporal mode. Most physicians do not do this, they just look at the most recent. Thus is one’s PSA goes from 1.2 to 2.8 in six months, I would recommend another three months later and then a biopsy.
Your survival is in your hands. Is it worth $100 a year? I would think so.

